Multidrug Resistance Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management
Condition: Multidrug-resistant Bacteria Screening Intervention: Diagnostic Test: molecular assays to screen for eXDR Sponsors: University Hospital, Grenoble; Becton, Dickinson and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 20, 2022 Category: Research Source Type: clinical trials

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial
This study will use a multicentre, open-label non-inferiority trial design comparing cefiderocol and standard of care antibiotics. Eligible participants will be adult inpatients who are diagnosed with a bloodstream infection with a Gram-negative organism on the basis of a positive blood culture result where the acquisition meets the definition for healthcare-associated or hospital-acquired. It will compare cefiderocol with the current standard of care (SOC) antibiotic regimen according to the patient ’s treating clinician. Eligible participants will be randomised 1:1 to cefiderocol or SOC and receive 5–14 days of ant...
Source: Trials - December 7, 2021 Category: Research Source Type: clinical trials

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan
ConclusionsThis qualitative analysis highlights ways in which insights developed together with patients and healthcare workers might inform approaches towards improved recruitment into trials, with the overall objective of delivering evidence for better treatments. (Source: Trials)
Source: Trials - December 4, 2021 Category: Research Source Type: clinical trials

Bioneer Accupower Q-RFIA PCR Kit Clinical Evaluation
Condition: Tuberculosis, Multidrug-Resistant Intervention: Sponsors: Foundation for Innovative New Diagnostics, Switzerland; V. N. Karazin Kharkiv National University; Kenya Medical Research Institute; Universidad Peruana Cayetano Heredia; Bioneer Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 11, 2021 Category: Research Source Type: clinical trials